NREP
NEW REPRESENTATIVE AT IB RECEIVED
23/04/2026
Voltar para busca
Dado oficial do USPTO
ASCENTAGE PHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
39
Atualização mais recente
24/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
42
Data de depósito
14/03/2022
Data de registro
07/11/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/11/2023
Última transação
24/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
98
Localização do titular
CN
Examinador
YARD, JOHN S
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a stylized letter A incorporating a curved band to the left of the stylized wording ASCENTAGE PHARMA.
Titulares e representantes
Titulares
ASCENTAGE PHARMA (SUZHOU) CO., LTD.
Jiangsu Ascentage Pharma Inc.
Representantes
Kathryn E. Smith Wood Herron & Evans LLP
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Scientific and medical research servicesstudies for combined compound functional mechanism on animals; cancer research for medical purposes; pharmaceutical research and developmentearly evaluation for implementation of the new drugs; pharmaceutical research; scientific surveys for medical purposes; chemical analysis services; research and analysis in the field of biochemistry; chemical research service; scientific and medical research services in the nature of chemical analysis assessment service; chemical research and analysis; scientific and medical research services in the nature of chemical synthesis assessment service; chemical analysis; chemistry consulting services; chemical research; cosmetic research; structural and functional analysis of genomes; stem cell research services; biotechnological research; blood analysis service; genetic screening for scientific purposes; biological cloning services; research and development of antibodies; genetic testing for scientific research purposes; bacteriological research and analysis; biomedical research; medical research; pharmaceutical drug development; medical laboratory service; development of pharmaceutical preparations and pharmaceuticals; medical research service; biological research and analysis; bacteriological research; biological research; scientific and medical researchnamely conducting clinical trials for others; computer programming of medical aspects; scientific and technical servicestesting and evaluation of pharmaceuticals; pharmaceutical research
Publicações
Histórico de despachos e eventos da marca no USPTO.
39 publicações encontradas
CHLD
CHANGE OF OWNER RECEIVED FROM IB
07/11/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/08/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
21/08/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/08/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/08/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/08/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
21/08/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/03/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/02/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/02/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/02/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/02/2024
FIMP
FINAL DISPOSITION PROCESSED
08/02/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/02/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/11/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
07/11/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
31/10/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/10/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
11/10/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
22/08/2023
PUBO
PUBLISHED FOR OPPOSITION
22/08/2023
GPNX
NOTIFICATION PROCESSED BY IB
21/08/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/08/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/08/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/08/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/07/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/07/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/07/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/07/2023
RFNT
REFUSAL PROCESSED BY IB
15/03/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
22/02/2023
RFRR
REFUSAL PROCESSED BY MPU
22/02/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
27/12/2022
CNRT
NON-FINAL ACTION WRITTEN
26/12/2022
DOCK
ASSIGNED TO EXAMINER
25/12/2022
MAFR
APPLICATION FILING RECEIPT MAILED
10/05/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/05/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/05/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ASCENTAGE PHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.